265 related articles for article (PubMed ID: 12543892)
1. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.
Furuland H; Linde T; Ahlmén J; Christensson A; Strömbom U; Danielson BG
Nephrol Dial Transplant; 2003 Feb; 18(2):353-61. PubMed ID: 12543892
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
3. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D;
Lancet; 2007 Oct; 370(9596):1415-21. PubMed ID: 17950856
[TBL] [Abstract][Full Text] [Related]
4. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
Nicholas JC
Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Provenzano R; Shutov E; Eremeeva L; Korneyeva S; Poole L; Saha G; Bradley C; Eyassu M; Besarab A; Leong R; Liu CS; Neff TB; Szczech L; Yu KP
Nephrol Dial Transplant; 2021 Aug; 36(9):1717-1730. PubMed ID: 33629100
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
[TBL] [Abstract][Full Text] [Related]
9. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
10. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
Walker R; Pussell BA;
Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
[TBL] [Abstract][Full Text] [Related]
11. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
Levine AM; Salvato P; Leitz GJ;
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
Dunn CJ; Wagstaff AJ
Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life.
Abrams DI; Steinhart C; Frascino R
Int J STD AIDS; 2000 Oct; 11(10):659-65. PubMed ID: 11057937
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
18. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
19. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
20. Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study.
Frei U; Kwan JT; Spinowitz BS;
BMC Nephrol; 2009 Feb; 10():5. PubMed ID: 19243619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
